Company Overview and News

 
QSR Brands goes ahead with relisting

2018-10-15 thestar.com.my
PETALING JAYA: QSR Brands (M) Holdings Bhd, the operator of KFC and Pizza Hut restaurants in Malaysia, is going ahead with the relisting of its shares on Bursa Malaysia, even as other companies are putting initial public offering (IPO) plans on hold.
5053 BSMAF 1818

 
Trading ideas: OSK Holdings, Hibiscus, Alam Maritim, Muda, Vertice

2018-10-15 thestar.com.my
KUALA LUMPUR: OSK Holdings Bhd , Hibiscus Petroleum Bhd , Alam Maritim Resources Bhd , Muda Holdings Bhd and Vertice Bhd are among the stocks to watch, according to JF Apex Research.
3883 5115 5053 HIPEF 5199

 
KLCI seen holding on to gains, support at 1,730

2018-10-14 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI is seen holding on to its gains today, in line with the rebound at most global markets last Friday, with support seen at the 1,730-point level.
3883 5115 5053 HIPEF 5199

 
OSK Holdings decides not to proceed with listing of cables business on Hong Kong bourse

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The drastic change of market sentiment has dampened OSK Holdings Bhd’s plan to list its cable business, OCC Cables Ltd, on the Main Board of the Hong Kong Stock Exchange.
5347 TNABY 1945 5053 TNABF BSMAF 1818

 
OSK Holdings, FGV Holdings, Hibiscus Petroleum, Alam Maritim, Muda Holdings, Vertice and MyEG

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): Based on corporate announcements and news flow today, stocks in focus on Monday (Oct 15) may include OSK Holdings Bhd, FGV Holdings Bhd, Hibiscus Petroleum Bhd, Alam Maritim Resources Bhd, Muda Holdings Bhd, Vertice Bhd and MyEG Services Bhd.
3883 5115 5053 HIPEF 5199

 
OCC Cables to raise HK$149m in Hong Kong IPO

2018-10-05 theedgemarkets
OCC announcing the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong. Seen here are Ong (left) and Yeat.
5347 TNABY 1945 5053 TNABF BSMAF 1818

 
OCC Cables' Hong Kong IPO expected to raise HK$149m

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): OCC Cables Ltd, which is an indirect subsidiary of Bursa Malaysia-listed OSK Holdings Bhd, is expected to raise net proceeds of HK$149 million (RM78.82 million) via its initial public offering (IPO) on the main board of The Stock Exchange of Hong Kong Ltd.
5347 TNABY 1945 5053 TNABF

 
Willowglen bags RM8.62m maintenance contract

2018-06-22 theedgemarkets
KUALA LUMPUR (June 22): Willowglen MSC Bhd's subsidiary Willowglen Services Pte Ltd has bagged a RM8.62 million contract to undertake maintenance of 30 document management solutions (DMS) product data management (PDM) systems and the upgrade of 22 PDM system workstations.
0008 5053

6
Stocks with forward momentum amid volatility

2018-06-18 theedgemarkets
KUALA LUMPUR: After weak first-quarter financial results, stocks on Bursa Malaysia faced rating downgrades which largely eliminated buying opportunities following the post-general election market correction and a regional sell-off in May.
4634 5053 BSMAF 7034 1818

4
OSK may list cable ops in Hong Kong

2018-03-27 thestar.com.my
PETALING JAYA: OSK Holdings Bhd is considering a plan to list its cable business on the Hong Kong Stock Exchange.
5053 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...